Compugen (NASDAQ:CGEN) Downgraded to Hold Rating by StockNews.com

StockNews.com cut shares of Compugen (NASDAQ:CGEN) from a buy rating to a hold rating in a research report sent to investors on Wednesday.

Separately, Oppenheimer began coverage on shares of Compugen in a research report on Monday, January 13th. They set an “outperform” rating and a $4.00 price target on the stock.

Compugen Trading Up 7.7 %

Shares of Compugen stock opened at $1.81 on Wednesday. The business’s fifty day simple moving average is $2.04 and its 200 day simple moving average is $1.84. The firm has a market capitalization of $161.52 million, a P/E ratio of 90.50 and a beta of 2.98. Compugen has a 12 month low of $1.35 and a 12 month high of $3.03.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Tuesday, March 4th. The biotechnology company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.14). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The business had revenue of $1.47 million during the quarter, compared to the consensus estimate of $17.47 million. Analysts predict that Compugen will post -0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Compugen

Hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC increased its position in shares of Compugen by 74.0% during the 4th quarter. Squarepoint Ops LLC now owns 290,659 shares of the biotechnology company’s stock valued at $445,000 after purchasing an additional 123,641 shares during the last quarter. Two Sigma Advisers LP raised its holdings in Compugen by 93.6% in the 4th quarter. Two Sigma Advisers LP now owns 35,784 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 17,300 shares during the period. Millennium Management LLC lifted its position in Compugen by 77.5% during the fourth quarter. Millennium Management LLC now owns 359,397 shares of the biotechnology company’s stock valued at $550,000 after purchasing an additional 156,959 shares in the last quarter. Jane Street Group LLC bought a new stake in Compugen during the fourth quarter valued at about $81,000. Finally, Northern Trust Corp increased its position in Compugen by 936.9% in the fourth quarter. Northern Trust Corp now owns 941,825 shares of the biotechnology company’s stock worth $1,441,000 after buying an additional 850,997 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.